| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b758fecaba243429625442aa212e8701 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-87
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate |
2016-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_394bc49458b653822305a19a5eb47563
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bf04b52b19cbbc9916031a59a74d701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ce7c3151f7bb9ef868ae63f1602bd36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55f3bf29576ccfc2797d050702b7eed9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbd65b07ac755e0e2357c03624021a37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dda03905b6416da49673812ae4a8d443 |
| publicationDate |
2016-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016354372-A1 |
| titleOfInvention |
Compositions and methods for treating neurological disorders |
| abstract |
The present disclosure provides methods for treating neurological disorders, generally involving modulating protein kinase D1 (PKD1) activity levels in a neuron or glial cell in an individual in need thereof. The present disclosure provides antibodies specific for PKD1. The present disclosure provides a genetically modified non-human mammal deficient in PKD1 activity. |
| priorityDate |
2010-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |